CoChat

Emerging implications of policies on malaria treatment: genetic changes in the Pfmdr-1 gene affecting susceptibility to artemether–lumefantrine and artesunate–amodiaquine in Africa

Okell, Lucy C, Reiter, Lisa Malene, Ebbe, Lene Sandø, Baraka, Vito, Bisanzio, Donal, Watson, Oliver J, Bennett, Adam, Verity, Robert, Gething, Peter, Roper, Cally, Alifrangis, Michael · 2018 · BMJ Global Health
Cited by 110

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Artemether–lumefantrine (AL) and artesunate–amodiaquine (AS-AQ) are the most commonly used artemisinin-based combination therapies (ACT) for treatment of Plasmodium falciparum in Africa. Both treatments remain efficacious, but single nucleotide polymorphisms (SNPs) in the P lasmodium falciparum multidrug resistance 1 (Pfmdr1) gene may compromise sensitivity. AL and AS-AQ exert opposing selective pressures: parasites with genotype 86Y, Y184 and 1246Y are partially resistant to AS-AQ treatment, while N86, 184 F and D1246 are favoured by AL treatment. Through a systematic review, we identified 397 surveys measuring the prevalence of Pfmdr1 polymorphisms at positions 86 184 or 1246 in 30 countries in Africa. Temporal trends in SNP frequencies after introduction of AL or AS-AQ as first-line treatment were analysed in 32 locations, and selection coefficients estimated. We examined associations between antimalarial policies, consumption, transmission intensity and rate of SNP selection. 1246Y frequency decreased on average more rapidly in locations where national policy recommended AL (median selection coefficient(s) of −0.083), compared with policies of AS-AQ or both AL and AS-AQ (median s=−0.035 and 0.021, p<0.001 respectively). 86Y frequency declined markedly after ACT policy introduction, with a borderline significant trend for a more rapid decline in countries with AL policies (p=0.055). However, these trends could also be explained by a difference in initial SNP frequencies at the time of ACT introduction. There were non-significant trends for faster selection of N86 and D1246 in areas with higher AL consumption and no trend with transmission intensity. Recorded consumption of AS-AQ was low in the locations and times Pfmdr1 data were collected. SNP trends in countries with AL policies suggest a broad increase in sensitivity of parasites to AS-AQ, by 7–10 years after AL introduction. Observed rates of selection have implications for planning strategies to cycle drugs or use multiple first-line therapies to maintain drug efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjgh-2018-000999

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 61

  1. Farooq, 2004, Drug resistance in malaria, J Vector Borne Dis, 41, 45
  2. 10.1038/nrdp.2017.50 · DOI · Paper page
  3. 10.4269/ajtmh.14-0031 · DOI · Paper page
  4. Thanh, 2017, Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of vietnam, Malar J, 16, 10.1186/s12936-017-1680-8 · DOI · Paper page
  5. 10.1038/nature12876 · DOI · Paper page
  6. Borrmann, 2011, Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast, PLoS One, 6, 10.1371/journal.pone.0026005 · DOI
  7. Tinto, 2014, Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change, Malar J, 13, 10.1186/1475-2875-13-207 · doi:10.1186/1475-2875-13-207
  8. Bennett, 2017, Population coverage of artemisinin-based combination treatment in children younger than 5 years with fever and Plasmodium falciparum infection in Africa, 2003-2015: a modelling study using data from national surveys, Lancet Glob Health, 5, e418, 10.1016/S2214-109X(17)30076-1 · DOI · Paper page
  9. 10.1038/345255a0 · DOI
  10. Veiga, 2016, Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies, Nat Commun, 7, 10.1038/ncomms11553 · DOI · Paper page
  11. 10.1016/j.febslet.2011.04.042 · DOI · Paper page
  12. 10.1016/S0140-6736(04)16767-6 · DOI · Paper page
  13. 10.1016/j.meegid.2007.03.005 · doi:10.1016/j.meegid.2007.03.005
  14. 10.1086/427997 · DOI · Paper page
  15. 10.1128/AAC.03647-14 · DOI
  16. 10.1128/AAC.50.5.1893-1895.2006 · DOI
  17. 10.1128/AAC.00875-06 · DOI · Paper page
  18. Otienoburu, 2016, Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia, Malar J, 15, 10.1186/s12936-016-1503-3 · doi:10.1186/s12936-016-1503-3
  19. Sondo, 2016, Artesunate-amodiaquine and artemether-lumefantrine therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso, PLoS One, 11, 10.1371/journal.pone.0151565 · DOI
  20. Dama, 2017, Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether-lumefantrine treatment in Mali, Malar J, 16, 10.1186/s12936-017-1700-8 · doi:10.1186/s12936-017-1700-8
  21. 10.1128/AAC.00638-09 · DOI · Paper page
  22. 10.1128/AAC.03494-14 · doi:10.1128/aac.03494-14
  23. 10.1093/infdis/jiu358 · DOI
  24. 10.1093/infdis/jis747 · DOI
  25. 10.1093/infdis/jiv551 · DOI
  26. Nguyen, 2015, Optimum population-level use of artemisinin combination therapies: a modelling study, Lancet Glob Health, 3, e758, 10.1016/S2214-109X(15)00162-X · DOI
  27. Baraka, 2018, Impact of treatment and re-treatment with artemether-lumefantrine and artesunate-amodiaquine on selection of plasmodium falciparum multidrug resistance gene-1 polymorphisms in the democratic republic of Congo and Uganda, PLoS One, 13, 10.1371/journal.pone.0191922 · doi:10.1371/journal.pone.0191922
  28. 10.1128/AAC.03554-14 · doi:10.1128/aac.03554-14
  29. 10.4269/ajtmh.2012.12-0308 · DOI
  30. Okell, 2017, Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa, Sci Rep, 7, 10.1038/s41598-017-06708-9 · DOI
  31. 10.1093/molbev/msw228 · DOI
  32. 10.1073/pnas.78.10.6344 · DOI
  33. 10.1016/S0140-6736(03)12951-0 · DOI · Paper page
  34. Heisig J , Schaeffer M . It Just ain't dope to drop the slope! why you should always include a random slope for the lower-level variable of a cross-level interaction. 2018.doi:doi:10.17605/OSF.IO/BWQTD · DOI
  35. Bell A , Fairbrother M , Jones K , 2018. Fixed vs random effects: making an informed choice (in review). www.researchgate.net/publication/299604336 · DOI · Paper page
  36. Fröberg, 2012, Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine despite its wide scale use as ACT partner drug in Zanzibar, Malar J, 11, 10.1186/1475-2875-11-321 · DOI
  37. 10.1111/j.1365-2958.2004.04470.x · doi:10.1111/j.1365-2958.2004.04470.x
  38. 10.1128/AAC.00950-12 · doi:10.1128/aac.00950-12
  39. 10.1086/522154 · DOI · Paper page
  40. 10.1093/infdis/jiq038 · doi:10.1093/infdis/jiq038
  41. Taylor, 2017, Artemether-lumefantrine and dihydroartemisinin-piperaquine exert inverse selective pressure on Plasmodium Falciparum drug sensitivity-associated haplotypes in Uganda, Open Forum Infect Dis, 4, 10.1093/ofid/ofw229 · doi:10.1093/ofid/ofw229
  42. Morris, 2015, Characterising temporal trends in asymptomatic Plasmodium infections and transporter polymorphisms during transition from high to low transmission in Zanzibar, 2005-2013, Infect Genet Evol, 33, 110, 10.1016/j.meegid.2015.04.018 · DOI
  43. Morris, 2015, Field deployment of loop-mediated isothermal amplification for centralized mass-screening of asymptomatic malaria in Zanzibar: a pre-elimination setting, Malar J, 14, 10.1186/s12936-015-0731-2 · DOI
  44. Klein, 2008, Clinically immune hosts as a refuge for drug-sensitive malaria parasites, Malar J, 7, 10.1186/1475-2875-7-67 · DOI
  45. Watson, 2017, Modelling the drivers of the spread of Plasmodium falciparum hrp2 gene deletions in sub-Saharan Africa, Elife, 6, 10.7554/eLife.25008 · DOI
  46. O'Meara, 2006, Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria, PLoS Med, 3, 10.1371/journal.pmed.0030141 · DOI
  47. Raman, 2008, Differential effect of regional drug pressure on dihydrofolate reductase and dihydropteroate synthetase mutations in southern Mozambique, Am J Trop Med Hyg, 78, 256, 10.4269/ajtmh.2008.78.256 · DOI
  48. 10.1016/S1473-3099(12)70064-6 · DOI · Paper page
  49. 10.4269/ajtmh.2010.09-0401 · DOI
  50. Huber, 2016, Quantitative, model-based estimates of variability in the generation and serial intervals of Plasmodium falciparum malaria, Malar J, 15, 10.1186/s12936-016-1537-6 · DOI
  51. Eyase, 2013, The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011, PLoS One, 8, 10.1371/journal.pone.0064299 · DOI
  52. Shah, 2015, Assessment of molecular markers for anti-malarial drug resistance after the introduction and scale-up of malaria control interventions in western Kenya, Malar J, 14, 10.1186/s12936-015-0588-4 · doi:10.1186/s12936-015-0588-4
  53. 10.1128/AAC.00559-12 · DOI
  54. 10.1128/AAC.01894-15 · DOI
  55. 10.1007/s00436-012-2994-7 · doi:10.1007/s00436-012-2994-7
  56. Mbaye, 2016, Selection of N86F184D1246 haplotype of Pfmrd1 gene by artemether-lumefantrine drug pressure on Plasmodium falciparum populations in Senegal, Malar J, 15, 10.1186/s12936-016-1490-4 · DOI
  57. Guerra M , Neres R , Salgueiro P , et al . Plasmodium falciparum genetic diversity in continental equatorial guinea before and after introduction of artemisinin-based combination therapy. Antimicrob Agents Chemother 2017;61.doi:10.1128/AAC.02556-15 · DOI
  58. 10.1128/AAC.46.1.166-170.2002 · doi:10.1128/aac.46.1.166-170.2002
  59. 10.1073/pnas.0804628105 · DOI · Paper page
  60. Moser, 2018, A scalable ISFET sensing and memory array with sensor auto-calibration for on-chip real-time DNA Detection, IEEE Trans Biomed Circuits Syst, 12, 390, 10.1109/TBCAS.2017.2789161 · DOI
  61. Schallig, 2017, Randomised controlled trial of two sequential artemisinin-based combination therapy regimens to treat uncomplicated falciparum malaria in African children: a protocol to investigate safety, efficacy and adherence, BMJ Glob Health, 2, 10.1136/bmjgh-2017-000371 · DOI

Cited by

See all 110

Metadata

Authors
Okell, L. C., Reiter, L. M., Ebbe, L. S., Baraka, V., Bisanzio, D., Watson, O. J., Bennett, A., Verity, R., Gething, P., Roper, C., & Alifrangis, M.
Venue
BMJ Global Health
Publisher
BMJ
Published
2018-10
Volume
3
Issue
5
Pages
e000999
ISSN
2059-7908
Cited by
110
References
3
Language
en
Funders
  • Bill and Melinda Gates Foundation
  • Royal Society (Dorothy Hodgkin Fellowship)
  • Medicines for Malaria Venture

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emerging implications of policies on malaria treatment: genetic changes in the Pfmdr-1 gene affecting susceptibility to artemether–lumefantrine and artesunate–amodiaquine in Africa. https://app.cochat.ai/papers/10.1136/bmjgh-2018-000999
The paper
Okell, L. C., Reiter, L. M., Ebbe, L. S., Baraka, V., Bisanzio, D., Watson, O. J., Bennett, A., Verity, R., Gething, P., Roper, C., & Alifrangis, M. (2018). Emerging implications of policies on malaria treatment: genetic changes in the Pfmdr-1 gene affecting susceptibility to artemether–lumefantrine and artesunate–amodiaquine in Africa. BMJ Global Health. https://doi.org/10.1136/bmjgh-2018-000999

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.